# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Sean Lee maintains Virios Therapeutics (NASDAQ:VIRI) with a Neutral, adjusts target to $5 from ...
Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), and Wex Pharmaceuticals, Inc. ("WEX"), a wholly owned ...